Physician profile
Hamza Hafeez
NPI 1467958025
$31,915.59
in general payments reported to CMS, 2019-2025
19 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $35.95 · 2021: $66.49 · 2022: $741 · 2023: $929 · 2024: $5,351 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $26K · Food and Beverage: $3,450 · Travel and Lodging: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $26,196.00 |
| Food and Beverage | $3,449.60 |
| Travel and Lodging | $1,305.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18,096.74 | 2023-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Abbott Laboratories | $9,176.64 | 2022-2025 | Mitraclip, Cardiomems |
| Boston Scientific Corporation | $2,123.59 | 2023-2025 | Avvigo Guidance System, Sentinel |
| Pfizer INC. | $524.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $339.88 | 2022-2024 | Camzyos, Eliquis |
| Shockwave Medical, INC | $273.68 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $256.98 | 2022-2023 | Xarelto |
| Abiomed | $182.18 | 2022 | |
| Impulse Dynamics (USA) INC. | $172.41 | 2023-2025 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $164.60 | 2022-2025 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $153.91 | 2021-2025 | Lifevest |
| Philips North America LLC | $127.50 | 2025 | Labosys |
| Angiodynamics, INC. | $111.20 | 2025 | Alphavac, Angiovac |
| Novartis Pharmaceuticals Corporation | $58.63 | 2022-2023 | |
| Amgen INC. | $44.63 | 2024-2025 | Repatha, Repatha |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $35.95 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.71 | 2025 | |
| W. L. Gore & Associates, INC. | $21.67 | 2025 | Gore Cardioform Septal Occluder |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.67 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Hafeez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.